NCT05065710: A Study of ZL-1211 in Patients With Advanced Solid Tumor

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T cell therapy; Patients with symptomatic brain metastases – see trial for details

Comments are closed.

Up ↑